Prostate Cancer Proteomics: Current Trends and Future Perspectives for Biomarker Discovery

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Jan 7

PMID 28061466

Citations 32

Authors

Cristiana Pistol Tanase

Elena Codrici

Ionela Daniela Popescu

Simona Mihai

Ana-Maria Enciu

Laura Georgiana Necula

Adrian Preda

Gener Ismail

Radu Albulescu

Affiliations

Soon will be listed here.

Abstract

The clinical and fundamental research in prostate cancer - the most common urological cancer in men - is currently entering the proteomic and genomic era. The focus has switched from one single marker (PSA) to panels of biomarkers (including proteins involved in ribosomal function and heat shock proteins). Novel genetic markers (such as Transmembrane protease serine 2 (TMPRSS2)-ERG fusion gene mRNA) or prostate cancer gene 3 (PCA3) had already entered the clinical practice, raising the question whether subsequent protein changes impact the evolution of the disease and the response to treatment. Proteomic technologies such as MALDI-MS, SELDI-MS, i-TRAQ allow a qualitative/quantitative analysis of the proteome variations, in both serum and tumor tissue. A new trend in prostate cancer research is proteomic analysis of prostasomes (prostate-specific exosomes), for the discovery of new biomarkers. This paper provides an update of novel clinical tests used in research and clinical diagnostic, as well as of potential tissue or fluid biomarkers provided by extensive proteomic research data.

Citing Articles

Advancements in Biomarkers of Prostate Cancer: A Review.

Agbetuyi-Tayo P, Gbadebo M, Rotimi O, Rotimi S Technol Cancer Res Treat. 2024; 23:15330338241290029.

PMID: 39440372 PMC: 11497500. DOI: 10.1177/15330338241290029.

Metabolomics and Proteomics in Prostate Cancer Research: Overview, Analytical Techniques, Data Analysis, and Recent Clinical Applications.

Al-Daffaie F, Al-Mudhafar S, Alhomsi A, Tarazi H, Almehdi A, El-Huneidi W Int J Mol Sci. 2024; 25(10).

PMID: 38791108 PMC: 11120916. DOI: 10.3390/ijms25105071.

Proteomics of prostate cancer serum and plasma using low and high throughput approaches.

Hamza G, Raghunathan R, Ashenden S, Zhang B, Miele E, Jarnuczak A Clin Proteomics. 2024; 21(1):21.

PMID: 38475692 PMC: 10929178. DOI: 10.1186/s12014-024-09461-0.

Tumor suppressive miR-99b-5p as an epigenomic regulator mediating mTOR/AR/SMARCD1 signaling axis in aggressive prostate cancer.

Waseem M, Gujrati H, Wang B Front Oncol. 2023; 13:1184186.

PMID: 38023145 PMC: 10661933. DOI: 10.3389/fonc.2023.1184186.

Proteomic analysis investigating kidney transplantation outcomes- a scoping review.

Rainey A, Mckay G, English J, Thakkinstian A, Maxwell A, Corr M BMC Nephrol. 2023; 24(1):346.

PMID: 37993798 PMC: 10666386. DOI: 10.1186/s12882-023-03401-0.

References

Crawford E, Scholz M, Kar A, Fegan J, Haregewoin A, Kaldate R . Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry. Curr Med Res Opin. 2014; 30(6):1025-31. DOI: 10.1185/03007995.2014.899208. View

Davalieva K, Polenakovic M . Proteomics in diagnosis of prostate cancer. Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2015; 36(1):5-36. View

Almufti R, Wilbaux M, Oza A, Henin E, Freyer G, Tod M . A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment. Ann Oncol. 2013; 25(1):41-56. DOI: 10.1093/annonc/mdt382. View

Geisler C, Gaisa N, Pfister D, Fuessel S, Kristiansen G, Braunschweig T . Identification and validation of potential new biomarkers for prostate cancer diagnosis and prognosis using 2D-DIGE and MS. Biomed Res Int. 2015; 2015:454256. PMC: 4312578. DOI: 10.1155/2015/454256. View

Yocum A, Khan A, Zhao R, Chinnaiyan A . Development of selected reaction monitoring-MS methodology to measure peptide biomarkers in prostate cancer. Proteomics. 2010; 10(19):3506-14. DOI: 10.1002/pmic.201000023. View

Cheung P, Woolcock B, Adomat H, Sutcliffe M, Bainbridge T, Jones E . Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res. 2004; 64(17):5929-33. DOI: 10.1158/0008-5472.CAN-04-1216. View

Paliouras M, Zaman N, Lumbroso R, Kapogeorgakis L, Beitel L, Wang E . Dynamic rewiring of the androgen receptor protein interaction network correlates with prostate cancer clinical outcomes. Integr Biol (Camb). 2011; 3(10):1020-32. DOI: 10.1039/c1ib00038a. View

Wolters T, van der Kwast T, Vissers C, Bangma C, Roobol M, Schroder F . False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. Am J Surg Pathol. 2009; 34(1):35-43. DOI: 10.1097/PAS.0b013e3181c3ece9. View

Overbye A, Skotland T, Koehler C, Thiede B, Seierstad T, Berge V . Identification of prostate cancer biomarkers in urinary exosomes. Oncotarget. 2015; 6(30):30357-76. PMC: 4745805. DOI: 10.18632/oncotarget.4851. View

10.

Ummanni R, Mundt F, Pospisil H, Venz S, Scharf C, Barett C . Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform. PLoS One. 2011; 6(2):e16833. PMC: 3037937. DOI: 10.1371/journal.pone.0016833. View

11.

Velonas V, Woo H, Dos Remedios C, Assinder S . Current status of biomarkers for prostate cancer. Int J Mol Sci. 2013; 14(6):11034-60. PMC: 3709717. DOI: 10.3390/ijms140611034. View

12.

Sugie S, Mukai S, Yamasaki K, Kamibeppu T, Tsukino H, Kamoto T . Significant Association of Caveolin-1 and Caveolin-2 with Prostate Cancer Progression. Cancer Genomics Proteomics. 2015; 12(6):391-6. View

13.

Garbis S, Tyritzis S, Roumeliotis T, Zerefos P, Giannopoulou E, Vlahou A . Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J Proteome Res. 2008; 7(8):3146-58. DOI: 10.1021/pr800060r. View

14.

Thompson I, Pauler D, Goodman P, Tangen C, Lucia M, Parnes H . Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004; 350(22):2239-46. DOI: 10.1056/NEJMoa031918. View

15.

Popescu I, Codrici E, Albulescu L, Mihai S, Enciu A, Albulescu R . Potential serum biomarkers for glioblastoma diagnostic assessed by proteomic approaches. Proteome Sci. 2014; 12(1):47. PMC: 4189552. DOI: 10.1186/s12953-014-0047-0. View

16.

Endoh K, Nishi M, Ishiguro H, Uemura H, Miyagi Y, Aoki I . Identification of phosphorylated proteins involved in the oncogenesis of prostate cancer via Pin1-proteomic analysis. Prostate. 2011; 72(6):626-37. DOI: 10.1002/pros.21466. View

17.

Gupta A, Roobol M, Savage C, Peltola M, Pettersson K, Scardino P . A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer. 2010; 103(5):708-14. PMC: 2938258. DOI: 10.1038/sj.bjc.6605815. View

18.

Alaiya A, Al-Mohanna M, Aslam M, Shinwari Z, Al-Mansouri L, Al-Rodayan M . Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma. Int J Oncol. 2011; 38(4):1047-57. DOI: 10.3892/ijo.2011.937. View

19.

Ahmad I, Patel R, Singh L, Nixon C, Seywright M, Barnetson R . HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proc Natl Acad Sci U S A. 2011; 108(39):16392-7. PMC: 3182686. DOI: 10.1073/pnas.1101263108. View

20.

Principe S, Kim Y, Fontana S, Ignatchenko V, Nyalwidhe J, Lance R . Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. J Proteome Res. 2012; 11(4):2386-96. PMC: 3642074. DOI: 10.1021/pr2011236. View